title: Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
abstract: BACKGROUND
  The superiority of frontline intraperitoneal (IP) over intravenous (IV) chemotherapy is well established in the treatment of epithelial ovarian cancer. However, the role of IP chemotherapy in the second-line setting has rarely been investigated.
  
  
  METHODS
  Consecutive patients diagnosed with recurrent epithelial, tubal and peritoneal cancers between January 2000 and December 2012 were recruited using a propensity score-matching technique to adjust relevant risk factors.
  
  
  RESULTS
  In total, 310 patients were included in the final analysis (94 for platinum-refractory/resistant disease and 216 for platinum-sensitive disease). IP chemotherapy demonstrated significantly longer median progression-free survival than IV chemotherapy (4.9 vs. 2.4 months, p < 0.001, for platinum-refractory/resistant disease, and 9.8 vs. 6.9 months, p < 0.001, for platinum-sensitive disease).
  
  
  CONCLUSIONS
  Second-line IP chemotherapy confers longer progression-free survival than IV chemotherapy. Large-scale clinical trials should be conducted to validate the true efficacy.
authors.forename: Chien-Hsing
authors.initials: CH
authors.lastname: Lu
authors.forename: Yen-Hou
authors.initials: YH
authors.lastname: Chang
authors.forename: Wai-Hou
authors.initials: WH
authors.lastname: Lee
authors.forename: Yi
authors.initials: Y
authors.lastname: Chang
authors.forename: Chia-Wen
authors.initials: CW
authors.lastname: Peng
authors.forename: Chi-Mu
authors.initials: CM
authors.lastname: Chuang
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010984:Platinum / Q000737:chemistry / Q000627:therapeutic use*; D057216:Propensity Score
chemical_list: D000970:Antineoplastic Agents; D010984:Platinum